The floodgates are opening for the first wave of the mAb biosimilars launches in the two most rewarding pharmaceutical markets US and EU. Twelve biologics with global sales of more than USD 67 billion will be exposed to biosimilar competition before 20201 . As several big name Pharmaceutical companies are gearing up for the opportunity, the Indian companies are conspicuous by their absence. Despite a 15year history of biosimilar development and commercialization, Indian companies are nowhere in the race for biosimilars in either US or EU. So far, only Intas Pharmaceutical, of Indian origins, launched Accofil® , a filgrastim biosimilar, in Europe.
Read More
Richa Agrawal
Richa leads the biosimilar practice at RAS. Having followed the evolution of biosimilar industry in last five years, she has acquired relevant understanding of this space which she like to share in her posts.